Lindsay E. Clegg

The HOPE (Heart Outcomes Prevention Evaluation) Study: The design of a large, simple randomized trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events

F Mindlen, Roberto Nordaby, M I Soto Ruiz et al. · Queensland's institutional digital repository (The University of Queensland) · 1996 · 154 citations

Medicine, Cardiology, Pharmacotherapy +17

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial

Lindsay E. Clegg, Robert C. Penland, Srinivas Bachina et al. · Cardiovascular Diabetology · 2019 · 94 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Site-Specific Phosphorylation of VEGFR2 Is Mediated by Receptor Trafficking: Insights from a Computational Model

Lindsay E. Clegg, Feilim Mac Gabhann · PLoS Computational Biology · 2015 · 56 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +14

Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A <i>post hoc</i> analysis of the <scp>EXSCEL</scp> trial

Annemarie B. van der Aart‐van der Beek, Lindsay E. Clegg, Robert C. Penland et al. · Diabetes Obesity and Metabolism · 2020 · 36 citations · Full text

Pharmacy, Endocrinology, Pharmacotherapy +17

A computational analysis of in vivo VEGFR activation by multiple co-expressed ligands

Lindsay E. Clegg, Feilim Mac Gabhann · PLoS Computational Biology · 2017 · 33 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17